Core Insights - 2026 is anticipated to be a significant year for Genmab, particularly regarding its late-stage pipeline [1] - The focus will be on three brands: EPKINLY, Rina-S, and petosemtamab, all of which have received FDA breakthrough therapy designation [1] Company Pipeline - Each of the three brands is expected to provide meaningful data in 2025, which is crucial for investor attention [1] - The FDA breakthrough therapy designation for all three brands highlights their potential in the market [1]

Summary of Genmab FY Conference Call - March 11, 2026 Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Key Focus**: Late-stage pipeline products including EPKINLY, Rina-S, and petosemtamab Key Points Industry and Pipeline Developments - **2026 Significance**: A pivotal year for Genmab with multiple important readouts expected from its late-stage pipeline [2][3] - **FDA Breakthrough Therapy Designation**: All three key products (EPKINLY, Rina-S, petosemtamab) have received this designation, enhancing their development prospects [2] EPKINLY - **Upcoming Readouts**: - Potential full approval for refractory DLBCL in the first half of 2026 - Frontline DLBCL readout expected later in 2026 [4][10] - **Confidence in Trials**: High confidence in upcoming trials despite previous monotherapy trial not meeting overall survival endpoints due to confounding factors [5][6] - **Primary Endpoint**: Progression-Free Survival (PFS) is the primary endpoint for the upcoming trials, which is aligned with regulatory expectations [8] - **Commercial Potential**: If successful, EPKINLY could significantly expand its market, potentially reaching an additional 90,000 to 100,000 patients in frontline settings [13] Rina-S - **Key Study**: RAINFOL-01 study for second-line plus ovarian cancer is set to report in the second half of 2026 [22] - **Efficacy Data**: Previous data showed an overall response rate (ORR) exceeding 50%, with confidence in replicating this in upcoming trials [23] - **Market Opportunity**: Combined patient population for ovarian and endometrial cancer is approximately 120,000, with a favorable split [24] Petosemtamab - **Expected Data**: Anticipated readouts from one or two head and neck cancer trials in the second half of 2026 [30] - **Efficacy Metrics**: Previous data indicated a 63% overall response rate when combined with pembrolizumab, significantly higher than pembrolizumab monotherapy [32] - **Future Plans**: Plans to initiate a phase 3 trial in locally advanced head and neck cancer by the end of 2026 [33] Financial Outlook - **Peak Year Sales Estimates**: - EPKINLY: $3 billion+ - Rina-S: $2 billion+ - Petosemtamab: Multi-billion range [41] - **Growth Prospects**: Strong growth anticipated even after the loss of DARZALEX royalties, supported by a robust pipeline and ongoing clinical development plans [42] Operational Strategy - **Market Approach**: Genmab is building its own distribution network in key markets (U.S., Japan, Germany) while considering partnerships in other regions [38] - **Operational Efficiency**: The company is confident in managing operational expenses while scaling its business [39] Competitive Landscape - **Differentiation**: Rina-S is positioned as a potential best-in-class asset with a comprehensive clinical profile and ongoing trials across multiple indications [27][29] Additional Insights - **Thought Leader Feedback**: Positive feedback from thought leaders regarding EPKINLY's PFS data and its potential in combination therapies [7][18] - **Regulatory Engagement**: Ongoing discussions with regulators to ensure alignment on trial endpoints and data expectations [8] This summary encapsulates the critical insights and projections discussed during the Genmab FY conference call, highlighting the company's strategic focus on its late-stage pipeline and the anticipated impact on its market position and financial growth.

Genmab Conference Call Summary Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Year**: 2025 was highlighted as a strong year for Genmab, with significant financial growth and advancements in their late-stage pipeline, including three key programs: EPKINLY, Rina-S, and pivekimab [3][4] Financial Performance - **Revenue Growth**: Strong revenue growth was reported, alongside disciplined operational expenditure management, leading to profit flowing to the bottom line [3] - **Pipeline Progress**: The company has three late-stage programs with meaningful clinical data expected to support potential launches in 2027 [4] Key Programs and Commercial Opportunities EPKINLY - **Market Potential**: EPKINLY is viewed as a blockbuster medicine with a potential market opportunity exceeding $3 billion [6] - **Therapeutic Indications**: The program is expanding into earlier lines of therapy, particularly in second-line follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) [6][8] - **Clinical Data**: Positive performance in initial phases and robust uptake in community settings were noted [8][27] - **Regulatory Timeline**: Expected readouts for frontline DLBCL and second-line DLBCL trials in 2026, with potential regulatory submissions leading to a launch in 2027 [15][16] Rina-S - **Market Potential**: Rina-S has a peak opportunity estimated at over $2 billion, targeting multiple subsegments in gynecologic oncology [9][10] - **Clinical Trials**: Three ongoing phase 3 trials are in progress, with the first registrational readout expected in 2026 [9][10] - **Differentiation**: The program is positioned as potentially best-in-class with differentiated efficacy and safety profiles, allowing for longer durations of therapy [34][35] Pivekimab - **Market Potential**: Pivekimab is also projected to be a multi-billion dollar opportunity, with two ongoing phase 3 trials in head and neck cancer [11][12] - **Regulatory Timeline**: Expected readouts for these trials in 2026, with a potential launch in 2027 [11][12] Commercialization Strategy - **Market Readiness**: Genmab has been building its commercial infrastructure in the U.S., Japan, and Europe, preparing for the launches of Rina-S and pivekimab [18][22] - **Track Record**: The company has successfully launched TIVDAK and EPKINLY, which provides confidence for future launches [24][22] Competitive Landscape - **EPKINLY vs. Competitors**: EPKINLY is positioned to penetrate earlier lines of treatment and gain market share against other CD20 bispecific therapies [25][26] - **Rina-S Differentiation**: Rina-S is expected to outperform existing ADCs in ovarian cancer due to its efficacy across various folate receptor alpha expression levels [34][35] Milestones and Catalysts for 2026 - **Key Readouts**: Two phase 3 readouts for EPKINLY in DLBCL, and the first registrational data for Rina-S and pivekimab are anticipated in 2026, leading to potential launches in 2027 [52][54] - **Focus on Deleveraging**: The company aims to reduce its debt from the acquisition of Merus, targeting a gross leverage ratio of three times or below by the end of 2027 [50][51] Conclusion - Genmab is positioned for significant growth with multiple late-stage programs expected to yield positive clinical data and commercial opportunities in the coming years. The company’s strategic focus on commercialization and market readiness, alongside a strong pipeline, sets a promising outlook for future performance [4][12][54]

Summary of Genmab's Conference Call Company Overview - **Company**: Genmab - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Speakers**: Anthony Pagano (CFO and Executive VP), Yaron Werber (Biotech Team) Core Industry Insights - **Oncology Focus**: Genmab is heavily invested in oncology, with three late-stage programs: EPKINLY, Rina-S, and pidocentimab, all of which have received FDA Breakthrough Therapy designations [2][3] - **Revenue Growth**: The company is experiencing strong revenue growth, particularly from proprietary products like EPKINLY and TIVDAK, with an increasing percentage of recurring revenue [7][8] - **Future Projections**: Genmab anticipates continued revenue growth into 2026 and beyond, driven by the success of its late-stage programs and a robust internal pipeline [3][4] Financial Performance - **Revenue Profile**: The revenue quality has improved year-over-year, with a notable increase in the contribution from proprietary products [7] - **TIVDAK Performance**: TIVDAK is expected to remain flat in terms of growth, contributing approximately $20 million, while EPKINLY is the primary driver of revenue growth [9][12] - **EPKINLY Sales**: EPKINLY had global sales of DKK 468 million last year, with expectations for growth in 2026, particularly in the second-line follicular lymphoma segment [17][19] Product Pipeline and Launches - **Rina-S and pidocentimab**: Both are expected to have registrational readouts in the second half of 2026, with potential launches in 2027 or 2028 [21][22] - **Market Potential**: Rina-S has a peak sales potential of over $2 billion, while EPKINLY is projected to reach $3 billion [27][31] - **Regulatory Process**: The timeline for product launches will depend on the regulatory process following data readouts [22][23] Debt and Profitability - **Debt Management**: Genmab took on $5.5 billion of debt for the Mirati acquisition and aims to reduce gross leverage to below 3 times by the end of 2027 [39][40] - **Profitability Commitment**: The company is committed to maintaining significant profitability in 2026 and 2027, focusing on efficient investments and operational productivity [40][41] Royalty Contributions - **Royalty Business**: The royalty revenue is primarily driven by DARZALEX and Kesimpta, with expectations for growth in 2026 [58][59] - **Emerging Products**: Tecfidera is expected to contribute positively, although it remains a smaller product in the portfolio [58] Additional Insights - **Synergy Realization**: The acquisition of Mirati is not primarily synergy-driven, but Genmab is looking for productivity improvements across its business [55][56] - **Clinical Trial Dynamics**: The company is open to adjusting clinical trial parameters to enhance outcomes and timelines [24][25] This summary encapsulates the key points discussed during the conference call, highlighting Genmab's strategic focus on oncology, financial performance, product pipeline, and future growth prospects.

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][29] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [16][24] Business Line Data and Key Metrics Changes - EPKINLY achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - TIVDAK generated $164 million in sales, representing a 26% year-over-year increase, highlighting its continued market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - EPKINLY closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [17] - TIVDAK's launch in Germany showed strong, consistent uptake and positive physician feedback, indicating a successful entry into new markets [21][22] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation and investment prioritization [30][29] - The company anticipates continued momentum in EPKINLY and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [26][29] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating significant long-term growth potential [9] - Management highlighted the importance of maximizing first-mover advantage in second-line follicular lymphoma in the U.S. and anticipated approvals in Europe and Japan [19][20] Q&A Session Summary Question: Next steps for EPKINLY following EPCORE DLBCL-1 study results - Management confirmed that the 05 study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies regarding the data set [33][34] Question: Update on outpatient data for EPKINLY - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [41][44] Question: Expectations for Rina-S pivotal phase II readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [50][51] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [55][56] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [61] Question: EPKINLY frontline DLBCL trial expectations - Management emphasized that the primary endpoint is progression-free survival, with expectations for EPKINLY to be transformative in combination with R-CHOP [66][68]

Core Insights - AbbVie and Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial, showing that epcoritamab improved progression-free survival (PFS) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) compared to standard chemoimmunotherapy [2][3] Group 1: Trial Results - The EPCORE DLBCL-1 trial demonstrated a PFS improvement with a hazard ratio (HR) of 0.74 (95% CI 0.60 to 0.92), indicating a statistically significant benefit [2][3] - Improvements were also noted in complete response rates (CRR), duration of response (DoR), and time to next treatment for patients receiving epcoritamab [2] - However, the trial did not show a statistically significant improvement in overall survival (OS) with an HR of 0.96 (95% CI 0.77 to 1.20) [2] Group 2: Study Details - The trial enrolled 483 patients with R/R DLBCL, with 73% having received two or more prior lines of therapy, and all patients were ineligible for high-dose chemotherapy and autologous stem cell transplant [3] - EPCORE DLBCL-1 is the first Phase 3 study to show PFS improvement using a CD3xCD20 T-cell engaging bispecific monotherapy [3] Group 3: Safety and Regulatory Actions - Adverse events observed were consistent with the known safety profile of epcoritamab, and the companies are assessing the impact of external factors such as the COVID-19 pandemic on trial outcomes [4] - AbbVie and Genmab plan to engage global regulatory authorities to discuss next steps following the trial results [4] Group 4: Background on DLBCL - DLBCL accounts for approximately 25-30% of all non-Hodgkin lymphoma (NHL) cases, with around 25,000 new cases diagnosed annually in the U.S. [5] - This type of lymphoma is fast-growing and primarily affects B-cell lymphocytes, with management remaining challenging despite new therapies [5] Group 5: Epcoritamab Overview - Epcoritamab, known as EPKINLY in the U.S. and Japan, and TEPKINLY in the EU, has received regulatory approval in over 65 countries for certain lymphoma indications [6][9] - The drug is being evaluated in ongoing clinical programs as both a monotherapy and in combination regimens across various hematologic malignancies [6][10]

Core Insights - Genmab announced topline results from the Phase 3 EPCORE DLBCL-1 trial, showing that epcoritamab monotherapy improved progression-free survival (PFS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1][2] - The trial demonstrated an overall survival (OS) hazard ratio of 0.96, which did not reach statistical significance [1] - Genmab and AbbVie will engage with global regulatory authorities to discuss next steps following the trial results [3] Study Details - The EPCORE DLBCL-1 trial enrolled 483 patients with R/R DLBCL, with 73% having received two or more prior lines of therapy [2] - The study compared epcoritamab monotherapy to investigator's choice of chemotherapy regimens, including rituximab plus gemcitabine and oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) [2][8] - The trial is ongoing and started on January 13, 2021 [8] Safety and Efficacy - Adverse events observed were consistent with the known safety profile of epcoritamab [3] - Further analysis of results is ongoing, considering factors like the COVID-19 pandemic and the availability of new anti-lymphoma therapies [3] Future Trials - Data is expected in 2026 from two additional Phase 3 trials evaluating epcoritamab in different treatment settings for DLBCL [4] - These trials include EPCORE DLBCL-2, assessing epcoritamab in combination with standard-of-care R-CHOP, and EPCORE DLBCL-4, comparing epcoritamab with lenalidomide against chemo-immunotherapy [4][12] Company Commitment - Genmab's CEO emphasized the significance of the EPCORE DLBCL-1 trial results in supporting epcoritamab as a core therapy for B-cell malignancies [5] - Epcoritamab has received regulatory approval in over 65 countries for certain lymphoma indications and is co-developed with AbbVie [5][11]

Summary of Genmab's ASH 2025 Update Company Overview - **Company**: Genmab - **Event**: ASH 2025 update and R&D review Key Highlights 1. **Strategic Acquisitions and Growth** - Genmab proposed the acquisition of Mirus and added Pathosentomab to its portfolio, positioning for sustained growth and long-term value creation [3][4] - The integration of Mirus is a key priority for 2026, with expectations for the transaction to close in Q1 2026 [4] 2. **Pipeline Developments** - Significant progress in the development of RINA-S, with three phase three trials and two phase two potentially registrational trials ongoing [5] - Epcoritamab has shown promising results in various lymphoma settings, with 31 abstracts accepted at ASH, including seven oral presentations [9][10] 3. **Epcoritamab Data** - In the EPCORE FL-1 study, the addition of epcoritamab to R squared resulted in a 79% risk reduction in progression or death, with a hazard ratio of 0.21 [17] - Overall response rate was 95% for the combination versus 79% for R squared alone, with a complete response rate of 83% compared to 50% [18] - The study demonstrated a significant improvement in duration of response, with a hazard ratio of 0.19 [19] 4. **Regulatory Approvals** - Epcoritamab received FDA approval for the treatment of follicular lymphoma after at least one line of therapy [25] - Ongoing global regulatory submissions are expected to be positively received [25] 5. **Future Expectations** - 2026 is anticipated to be a year of important catalysts, including multiple potential registrational data sets for EPCORE, RINA-S, and beta centromere [34] - Genmab aims to advance its evolution into a global biotech leader with a diversified, fully integrated model [35] Industry Context - **Oncology Market** - The oncology community is seeing a shift towards bispecific antibodies like epcoritamab, which offer off-the-shelf solutions and are easier to administer compared to CAR-T therapies [46] - Epcoritamab's subcutaneous administration and manageable safety profile are key differentiators for adoption in community settings [37] Additional Insights - **Safety and Tolerability** - Epcoritamab's safety profile showed manageable adverse events, with no severe cytokine release syndrome reported [21][22] - Proactive management of infections is emphasized, particularly in outpatient settings [23][40] - **Comparative Efficacy** - The discussion around sequencing CAR-T and bispecific therapies indicates that bispecifics may serve as effective bridging therapies before CAR-T cell collection [44] - The potential for improved overall survival with epcoritamab in comparison to existing therapies is a focal point for future studies [51] This summary encapsulates the key points from Genmab's ASH 2025 update, highlighting the company's strategic direction, pipeline advancements, and the evolving landscape of oncology treatments.

Core Insights - Genmab has made significant advancements in its late-stage portfolio, with Epcoritamab nearing availability for earlier treatment lines in follicular lymphoma and Rina-S receiving Breakthrough Therapy Designation for advanced endometrial cancer [2][6] - The proposed acquisition of Merus is expected to enhance Genmab's late-stage pipeline by adding petosemtamab, which has two Breakthrough Therapy Designations, and is anticipated to drive sustained growth into the next decade [2][8] Financial Performance - Genmab's revenue for the first nine months of 2025 reached $2,662 million, a 21% increase from $2,198 million in the same period of 2024, primarily driven by higher royalties from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY [6][7] - Royalty revenue increased to $2,219 million in the first nine months of 2025, up from $1,802 million in the same period of 2024, marking a 23% rise [7] - Operating profit for the first nine months of 2025 was $1,007 million, compared to $662 million in the same period of 2024 [7] Strategic Outlook - Genmab is maintaining its financial guidance for 2025 as published on August 7, 2025 [4] - The company has transitioned its functional and presentation currency from DKK to USD effective January 1, 2025, with retrospective adjustments made to prior periods [5] Acquisition Details - Genmab intends to acquire Merus for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion, funded through cash on hand and $5.5 billion of non-convertible debt financing [8] - The acquisition is expected to close by early Q1 2026, subject to customary closing conditions [8]

Summary of Genmab's Conference Call on Proposed Acquisition of Merus N.V. Company and Industry - **Company**: Genmab (NasdaqGS: GMAB) - **Industry**: Biotechnology, specifically focused on antibody-based therapies Core Points and Arguments 1. **Proposed Acquisition**: Genmab announced a transformative acquisition of Merus N.V. for $97 per share, totaling approximately $8 billion, expected to close in early Q1 2026, pending regulatory approvals [3][14][21] 2. **Strategic Importance**: The acquisition aligns with Genmab's vision to transition from a royalty-dependent model to a fully integrated biotech company that owns, develops, and commercializes its own medicines [4][5][19] 3. **Pipeline Enhancement**: The addition of petosemtamab (PETO) to Genmab's late-stage pipeline is expected to strengthen its position, with PETO having received two breakthrough therapy designations from the FDA [4][6][12] 4. **Market Potential**: PETO is anticipated to have multibillion-dollar peak sales potential, with an initial launch expected in 2027 [5][19] 5. **Clinical Development**: Genmab is confident in PETO's efficacy, with clinical trials showing a 36% response rate in second-line settings and a 63% response rate in first-line settings when combined with pembrolizumab [11][12] 6. **Financial Outlook**: The acquisition is projected to be accretive to EBITDA by 2029, with expectations of significant profitability in 2026 and meaningful growth in 2027 [16][19] 7. **Investment Strategy**: Genmab plans to invest in R&D and commercialization for PETO while maintaining profitability, with a commitment to rapid deleveraging post-acquisition [15][17][19] 8. **Long-term Vision**: The acquisition is seen as a key step towards achieving Genmab's 2030 vision of improving patient lives through innovative therapies [4][21] Additional Important Content 1. **Clinical Trials**: Two phase 3 trials for PETO are ongoing, with expected top-line data readouts in 2026 [10][60] 2. **Safety Profile**: PETO has shown a manageable safety profile, with infusion-related reactions primarily occurring during the first cycle [13][12] 3. **Competitive Landscape**: The potential for PETO to transform treatment in head and neck cancer is emphasized, particularly in settings where current therapies have limited efficacy [10][62] 4. **Platform Acquisition**: The acquisition of Merus N.V. is not just about PETO but also about integrating Merus's bispecific antibody technology platform, which complements Genmab's existing capabilities [90][92] 5. **Future Development**: Discussions on potential expansion into colorectal cancer are premature until more data is available, but the mechanism of action for PETO shows promise across different cancer types [52][84] This summary encapsulates the key points from Genmab's conference call regarding the acquisition of Merus N.V. and the strategic implications for the company's future in the biotechnology sector.